I was interested to read this recent publication in young people diagnosed with 'essential thrombocythemia' (ET). 1 I would however like to point out a few concerns regarding this article. Alvarez-Larrán et al. in their method section comment on utilizing Polycythaemia Vera Study Group diagnostic criteria for ET. This raises validity issues regarding the subset of patients studied, which is subsequently demonstrated in the clinicohematological data in Table 1. 1 A number of recent (retrospective) studies comparing PVSG diagnostic criteria versus World Health Organization (WHO) criteria 2 have demonstrated that ET diagnosed under PVSG criteria comprise patients with 'true' ET, polycythemia vera and chronic idiopathic myelofibrosis. 3, 4 In this article, five cases each of 'myelofibrosis' and polycythemia vera are outlined in Table 1 (combining JAK2-positive and -negative patients). The study cohort does not appear to be 'true' ET patients and as a result conclusions drawn are suboptimal. Figure 2b 1 is a clear example of incorporation of non-ET patients as they had grade 2 fibrosis at diagnosis. Perhaps the authors could comment on their results excluding the 'known' non-ET patients. A more thorough re-examination of bone marrows using current diagnostic criteria of either WHO or European clinical, molecular and pathological criteria 5 would strengthen the validity of this publication.
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Reply to 'Re: Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Westerman et al. 1 suggest that the Polycythemia Vera Study Group (PVSG) criteria for the diagnosis of essential thrombocythemia (ET) used in our study were inadequate 2 and that, as a consequence, some patients might have polycythemia vera or primary myelofibrosis (PMF) rather than ET at presentation. First of all, the PVSG criteria have been and are currently used for the diagnosis of chronic myeloproliferative disorders by most groups. 3, 4 Development of erythrocytosis is not a rare event in patients with ET. Thus, Jantunen et al. 5 reported the appearance of erythrocytosis in up to 6.5% of ET patients at a median of 29 months from ET diagnosis and, more recently, Campbell et al. 3 have reported polycythemic transformation in a minority of JAK2-positive patients diagnosed with ET according to the PVSG criteria. In our series, transition from ET to polycythemia vera was observed in five patients, all of them being women, at a median of 6 years (range: 5-9) from ET diagnosis, which represents 4% of the overall series, a figure that is in keeping with that previously reported by others. Of note, in these five women, median Hb level at diagnosis of ET was 135 g l À1 (range 120-149) and none of them fulfilled the A1 criteria of the WHO classification (that is, Hb4165 g l À1 ), which is mandatory for the diagnosis of polycythemia vera. 6 Myelofibrotic transformation was observed in 6 out of our 126 young ET patients. Based on the fact that 4 out of the 24 patients with a moderate degree of marrow fibrosis at ET diagnosis subsequently developed myelofibrosis, Westerman et al. put forward the possibility that these patients actually had PMF rather than true ET at presentation. Although the abovementioned four patients had grade 2 fibrosis in the bone marrow biopsy at the time of ET diagnosis, in accordance with the PVSG criteria for ET, none of them had collagen fibrosis in the marrow or displayed splenomegaly, anemia, dacryocytes or a leukoerytroblastic blood picture. Moreover, a careful review of the initial bone marrow biopsies allowed to rule out the so-called 'prefibrotic' form of myelofibrosis, since no patient had megakaryocytic dysplasia, which is considered a characteristic feature of this special form of PMF. 7 Therefore, based on the lack of clinical and histological features of myelofibrosis, 7 the possibility of PMF instead of ET at presentation was also excluded. It must also be noted that the majority of patients with moderate marrow fibrosis at diagnosis of ET (that is, the remaining 20 patients) did not develop myelofibrosis after a median follow-up of 10 years (range: 4-25). This observation would argue against considering the mere presence of some degree of fibrosis, in the absence of additional data suggesting PMF as sufficient to diagnose this disease.
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